Naturis Lab
Back to Insights

Arthritis and Cannabinoids: A Review of the Scientific Evidence.

Cannabinoides
Arthritis and Cannabinoids: A Review of the Scientific Evidence.

Arthritis is characterized by inflammation and pain in the joints, which can significantly limit quality of life. Among the most common types are rheumatoid arthritis (RA), osteoarthritis (OA) and psoriatic arthritis. In recent years, cannabinoids, compounds derived from the Cannabis sativa plant, have gained attention as potential treatments for the management of pain and inflammation associated with these conditions. While tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most studied cannabinoids, minor cannabinoids such as cannabichromene (CBC), cannabigerol (CBG), and cannabinol (CBN) are emerging as promising therapeutic options. We will explore the current scientific evidence on the use of these cannabinoids in the treatment of arthritis, with a special focus on minor cannabinoids, supported by recent studies.

What is arthritis?

Arthritis encompasses a group of diseases that cause inflammation, pain and stiffness in the joints. Rheumatoid arthritis is an autoimmune disease that primarily affects small joints, while osteoarthritis is a degenerative condition involving the wearing away of joint cartilage. Both forms share chronic pain as a primary symptom, leading patients to seek alternative treatments, including cannabinoids, especially when conventional treatments are ineffective. According to estimates, more than 10 million people in the United Kingdom and approximately 54 million in the United States suffer from some form of arthritis, underscoring the need for effective and safe therapies.

The Endocannabinoid System and its Role in Arthritis

The endocannabinoid system (ECS) is a key biological network that regulates processes such as pain, inflammation and immune response. It is composed of receptors (CB1 and CB2), endocannabinoids (such as anandamide and 2-AG) and metabolic enzymes. Phytocannabinoids, such as those found in cannabis, interact with these receptors, modulating inflammation and pain perception. In the context of arthritis, CB2 receptors, which are found mainly on immune cells, are particularly relevant because of their role in modulating inflammation.

In vitro studies have shown that synovial tissue from RA and OA patients contains elevated levels of endocannabinoids, such as anandamide, that are not present in healthy controls. In addition, stimulation of CB2 receptors in synovial cells of arthritis patients has shown inhibition of proinflammatory cytokines, suggesting a potential anti-inflammatory effect of cannabinoids.

Main Cannabinoids: THC and CBD

THC and CBD are the most studied cannabinoids. THC, known for its psychoactive effects, acts as a partial agonist of CB1 and CB2 receptors, which can reduce inflammation and pain. However, its use is limited by psychotropic effects and legal regulations in many countries. CBD, on the other hand, is non-psychoactive and has shown anti-inflammatory and analgesic properties by interacting with SEC and other receptors, such as TRPV1. A 2017 animal study found that CBD could block osteoarthritis pain and prevent further joint damage, making it a promising option.

Despite these findings, clinical evidence for CBD in humans remains limited. A systematic review by Fitzcharles et al. (2016) analyzed clinical trials with nabilone (a synthetic THC analog) and THC/CBD combinations in patients with rheumatoid arthritis and fibromyalgia, but found no consistent effects on pain compared with placebos or conventional treatments. In addition, the studies were at high risk of bias, highlighting the need for more robust research.

Minor Cannabinoids: CBC, CBG and CBN

The minor cannabinoids, although less abundant in the cannabis plant, are attracting increasing interest due to their unique therapeutic properties and lack of significant psychoactive effects. The following details the available evidence for each in the context of arthritis:

Cannabichromene (CBC)

CBC is a non-psychoactive cannabinoid derived from CBG. Although it does not bind strongly to CB1 or CB2 receptors, it interacts with TRPV1 and TRPA1 receptors, which are involved in pain perception. Preclinical studies suggest that CBC has analgesic and anti-inflammatory effects. For example, a study in rats showed that CBC may have neuroprotective and anti-inflammatory properties, which could be relevant for psoriatic arthritis, where skin and joint inflammation is prominent. In addition, CBC acts synergistically with other cannabinoids, enhancing the “entourage effect”, which could improve its efficacy in the management of chronic pain.

Cannabigerol (CBG)

CBG, a precursor of THC and CBD, is another non-psychoactive cannabinoid with anti-inflammatory and analgesic properties. It binds to CB1 and CB2 receptors, as well as the alpha-2 adrenergic receptor and the serotonin 5-HT1A receptor, which may contribute to its analgesic effects. A 2021 study found that CBG derivatives reduced inflammation and pain in animal models of inflammatory pain, in addition to decreasing the expression of proinflammatory cytokines such as TNF-α. In collagen-induced arthritis models, CBG and other selective CB2 agonists, such as JWH-133 and HU-308, showed beneficial effects, suggesting therapeutic potential for rheumatoid arthritis.

Cannabinol (CBN)

CBN, a breakdown product of THC, is mildly psychoactive (approximately 25% of the potency of THC) and has been studied for its sedative and analgesic properties. A 2019 Canadian study in rats showed that CBN, alone or in combination with CBD, relieved chronic muscle pain, similar to that experienced in fibromyalgia, a condition often associated with arthritis. In addition, CBN inhibits the formation of corneal cells, which could be useful in the treatment of psoriatic arthritis. However, research on CBN is limited, and its presence in low concentrations in the cannabis plant makes it difficult to study.

Clinical Evidence and Limitations

Despite the potential of cannabinoids, clinical evidence remains sparse and of low quality. A 2018 review by the Cochrane Collaboration found that studies of medical cannabis for neuropathic pain, including that associated with arthritis, were of short duration and at high risk of bias. In an analysis of 203 patients with RA, fibromyalgia, and OA, cannabinoids showed significant effects on pain and sleep in some studies, but the results were not consistent. Bodies such as the National Institute for Health Care Excellence (UK) and the French Society of Neurology have concluded that there is insufficient evidence to recommend cannabinoids as first-line treatment for chronic pain, reserving them for refractory cases.

The main limitations include:

  • Lack of large-scale studies: Most clinical trials have small samples and short durations.
  • High risk of bias: Many studies lack adequate controls or present methodological problems.
  • Variability in formulations: The composition of cannabis products varies, making comparison between studies difficult.
  • Adverse effects: Cannabinoids, especially THC and CBN in high doses, can cause side effects such as fatigue, nausea and dizziness.

Legal and Clinical Considerations

In countries such as Argentina and Mexico, the legalization of medical cannabis has facilitated research, but physicians still express caution due to a lack of solid data. In Europe, CBD is widely legal, but THC and other cannabinoids are regulated due to their psychoactive effects. Patients interested in using cannabinoids should consult a healthcare professional, especially if taking other medications, as CBD may interact with liver enzymes.

Conclusion

Cannabinoids, including minor ones such as CBC, CBG and CBN, show promising potential for the treatment of arthritis due to their anti-inflammatory and analgesic properties. Preclinical studies suggest that these compounds may modulate inflammation and pain through the endocannabinoid system and other mechanisms. However, clinical evidence is limited, and higher quality randomized controlled trials are needed to confirm their efficacy and safety. In the meantime, patients and physicians should weigh the potential benefits against the risks and consider cannabinoids as an adjunctive therapy in refractory cases. Future research, especially on minor cannabinoids, could open new doors for arthritis management, offering hope to millions of patients.

References

  1. Fitzcharles MA, et al. (2016). Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: A systematic review of randomized controlled trials. Arthritis Care & Research.
  2. Mücke M, et al. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews.
  3. Philpott HT, et al. (2017). Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain.
  4. Kogan NM, et al. (2021). Novel CBG derivatives can reduce inflammation, pain and obesity. Molecules.
  5. Wong SS, et al. (2019). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology.

(https://naturislab.com/en/laboratory-tests-as-a-guarantee-of-quality/)

(https://naturislab.com/en/laboratories-against-cbd-counterfeits/)

We are not just another laboratory.

We are your guarantee that every product delivers as promised.

Legal